M
Masakazu Toi
Researcher at Kyoto University
Publications - 658
Citations - 28522
Masakazu Toi is an academic researcher from Kyoto University. The author has contributed to research in topics: Breast cancer & Cancer. The author has an hindex of 69, co-authored 578 publications receiving 23200 citations. Previous affiliations of Masakazu Toi include The Breast Cancer Research Foundation & Tokyo Metropolitan Komagome Hospital.
Papers
More filters
Journal ArticleDOI
Comparison of different definitions of pathologic complete response in operable breast cancer: a pooled analysis of three prospective neoadjuvant studies of JBCRG
Katsumasa Kuroi,Masakazu Toi,Shinji Ohno,Seigo Nakamura,Hiroji Iwata,Norikazu Masuda,Nobuaki Sato,Hitoshi Tsuda,Masafumi Kurosumi,Futoshi Akiyama +9 more
TL;DR: Prognostic significance of pCR varied according to the definition of p CR, and the pattern of recurrence might be different according to pathologic response and subtype.
Journal ArticleDOI
RK-95113, a new angiogenesis inhibitor produced by Aspergillus fumigatus
TL;DR: Aspergillus fumigatus RK95-113 preferentially inhibited the growth of human umbilical vein endothelial cells (HUVECs) rather than that of human normal fibroblasts in cell proliferation assays and blocked endothlial cell migration induced by vascular endothelial growth factor (VEGF).
Journal ArticleDOI
The Sal-like 4 - integrin α6β1 network promotes cell migration for metastasis via activation of focal adhesion dynamics in basal-like breast cancer cells
Junji Itou,Sunao Tanaka,Wenzhao Li,Atsuo Iida,Atsuko Sehara-Fujisawa,Fumiaki Sato,Masakazu Toi +6 more
TL;DR: Results indicated that the SALL4 - integrin α6β1 network promotes cell migration via modulation of Rho activity, and zebrafish metastasis assays demonstrated that this gene network enhances cell migration in vivo.
Journal ArticleDOI
Pharmacokinetic and pharmacodynamic study of IST-622, a novel synthetic derivative of chartreusin, by oral administration in a phase II study of patients with breast cancer.
Gyo Asai,Nobuyuki Yamamoto,Masakazu Toi,Eisei Shin,Kiyoshi Nishiyama,Tomohisa Sekine,Yasuo Nomura,Shigemitsu Takashima,Morihiko Kimura,Takeshi Tominaga +9 more
TL;DR: Myelotoxicities showed a good correlation with AUC0–24h, and the possibility of predicting toxicities and dose adaptation for interpatient variability using LSM is shown.
Journal ArticleDOI
Overexpression of MDM2 in MCF-7 promotes both growth advantage and p53 accumulation in response to estradiol.
Shigehira Saji,Shigeru Nakashima,Shin Ichi Hayashi,Masakazu Toi,Shigetoyo Saji,Yoshinori Nozawa +5 more
TL;DR: It is suggested that MDM2 may regulate the expression of p53 in the steady state and in response to E2 in breast cancer cells, and imply a novel and important role ofMDM2 during breast carcinogenesis.